Search

everythinglearnresearchcommunity

for

Search:↓

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.

Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.

Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Testosterone therapy increases bone density in older men with low testosterone levels.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.

Using finasteride with TIP extends time off period for prostate cancer patients.

Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.

Men with vertex baldness may have a higher risk of developing prostate cancer, but more research is needed to confirm this.

The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.

Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.

Cancer development is like natural selection, involving mutated cells and environmental factors.

Large prostate links to more hair loss, but age of onset doesn't affect it.

MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.

11α-Hydroxyprogesterone is changed into different substances by certain enzymes and may play a role in prostate cancer.

Early onset baldness in men may indicate a condition similar to PCOS, linked to heart disease, diabetes, and prostate issues.

Men with certain types of baldness at age 45 may have a higher risk of colon cancer and colorectal adenoma.

Hormones affect prostate health and disease, with certain hormone imbalances linked to prostate cancer and benign prostatic hyperplasia.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

WNT10B is linked to cancer development and affects survival and disease progression in various cancers.

The study found stem cells in minor salivary glands that can differentiate and are involved in tumor formation when exposed to tobacco.

Women have a higher risk of blood clots from hormonal factors and need careful treatment, especially during pregnancy.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Researchers found 63 genes linked to male-pattern baldness, which could help in understanding its biology and developing new treatments.

Selective non-steroidal inhibitors of 5α-reductase type 1 can help treat DHT-related disorders.

The document concludes that sexual and psychiatric side effects from 5-alpha-reductase inhibitors are reported, but more high-quality research is needed to understand how often they occur.

The new particle system could be a promising treatment for diseases related to the 5-α reductase enzyme.

The document concludes that better research methods are needed in men's sexual health to provide stronger evidence and improve patient care.